In brief
New studies highlight India's rising threat from drug-resistant bacteria, prompting innovative solutions to tackle severe infections.
India's healthcare landscape is witnessing a pivotal shift as it develops novel antibiotics to counteract the surge of antibiotic-resistant infections. The country is grappling with a severe situation, with drug-resistant infections leading to approximately 300,000 deaths in 2019 alone. Antibiotics which once stood as a primary line of defense are now under siege from bacteria that mutate rapidly to evade their effects. Recent reports from The Lancet reveal that these "superbugs" were directly responsible for 1.14 million deaths globally in 2021. India, as one of the hardest-hit nations, faces an endemic struggle against antimicrobial resistance, particularly in critical care settings that pose lifethreatening risks, especially to vulnerable populations like newborns.However, advancements in pharmaceuticals are shedding light on potential breakthroughs. A key player is Orchid Pharma from Chennai, which successfully developed Enmetazobactam - the first Indian antimicrobial to gain approval from the US Food and Drug Administration (FDA). This injectable drug specifically targets bacterial defense mechanisms instead of the bacteria directly. It neutralizes beta-lactamase enzymes, which bacteria produce to fend off antibiotics, thereby enhancing the efficacy of associated treatments like carbapenems.Clinical trials spanning across 19 countries with over 1,000 patients have validated this drug's efficacy. Dr. Maneesh Paul, a pioneer behind the innovation, noted its critical administration via IV for patients in dire conditions, emphasizing that it is not accessible over the counter.Wockhardt, a Mumbai-based pharmaceutical company, is also on the frontlines, with a new antibiotic named Zaynich currently in Phase-3 trials. After 25 years of development, Zaynich has been shown to work on critically ill patients, resulting in a 100% survival rate among those it was administered to as a last resort. The founder, Dr. Habib Khorakiwala, believes this development positions India as a leader in global health solutions.In addition to Zaynich, Wockhardt is assessing Nafithromycin, branded as MIQNAF. This three-day oral treatment for bacterial pneumonia boasts a striking 97% success rate in trials, with expectations for a market launch by late next year.Progress isn’t limited to private sector advancements. The Bengaluru-based Bugworks Research, in collaboration with GARDP, is in the early phases of developing a new antibiotic class. CEO Anand Anandkumar highlights the financial imbalance in pharmaceutical R&D, with antibiotics frequently overlooked in favor of treatments for chronic conditions. Evidence shows that antibiotics are often marketed as a last resort, resulting in minimal innovation in this critical area.A recent Indian Council of Medical Research (ICMR) report raises alarm over rising antibiotic resistance, identifying E. coli as the most commonly isolated pathogen in a surveillance involving nearly 100,000 bacterial cultures. Concerns have spiked regarding the effectiveness of antibiotics, especially regarding critical last-resorts like carbapenems.Dr. Manica Balasegaram of GARDP notes the rapid evolution of resistant bacteria necessitates innovation in antibiotic research. Collaborations with companies worldwide are underway to explore novel treatments, including a partnership with Aurigene Pharmaceuticals to produce zoliflodacin for gonorrhea.Despite these promising developments, experts stress a comprehensive strategy is needed. Urgent reforms in antibiotic prescription practices are critical, given the ongoing misuse of broad-spectrum antibiotics. Wider adoption of narrow-spectrum alternatives is preferred.Dr. Kamini Walia of ICMR underscores that while new antibiotics may prove beneficial, they too may become ineffectual if not judiciously used. Enhancing sanitary conditions, boosting vaccination rates, and creating robust infection control policies are paramount in tackling antimicrobial resistance.The call to action is clear: without decisive interventions, we risk regressing into an era where infections, even minor ones, may become untreatable, posing a significant threat to public health globally.
